Peter Voorhees, MD, Discusses Updated Analysis of Phase 2 GRIFFIN Trial in MM

Video

The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

In an interview with CancerNetwork®, Peter Voorhees, MD, of the Levine Cancer Institute, spoke about findings from an updated analysis of the Phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

Transcription:

What we show with this updated analysis is that the rates of stringent [complete response (CR] continue to improve and clearly favor the daratumumab (Darzalex) arm. So, looking at stringent CR in the daratumumab arm, we're now up to 63.6% with one year of maintenance therapy, in contrast to 47.4% for those in the control arm and this is highly statistically significant. If we look at all complete responses stringent to non-stringent, it's close to 82% in the daratumumab compared to close to 61% in the control arm. When we look at MRD negativity, measured with [next generation sequencing] at a sensitivity level of 10-5 in the intent to treat analysis, the [minimal residual disease (MRD)] negative rate in the daratumumab arm is 62 and a half percent in contrast to 27% for those in the control arm. If we look at those patients specifically who have MRD evaluable disease, the rates of MRD negativity in the experimental arm of the daratumumab arm is 78%, in contrast to 39.5% in the control arm.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content